Full Press Release Details
Actinium Pharmaceuticals Issues
Mid-Year Letter to Shareholders Providing Update on Company Progress and Anticipated Milestones
NEW YORK, NY - August
4, 2016 - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or the "Company"), a biopharmaceutical
company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the
Company has issued a mid-year letter to shareholders highlighting Actinium's recent progress and anticipated corporate milestones.
The recent progress and anticipated milestones below were featured in the shareholder letter:
Key Achievements To-Date
Positive Outlook for the Remainder
Actinium's strategy over the next
two years is to be laser focused on executing both the Iomab-B and Actimab-A clinical trials and achieve clinical milestones in
order to pave the way for regulatory approvals and, where appropriate, facilitate corporate partnerships for these assets. With
the pivotal Phase 3 SIERRA trial for Iomab-B initiated and the Phase 2 portion of the Actimab-A trial imminent, we expect to continue
to evolve into a later-stage development company. To that end, we intend to continue our work to build shareholder value by targeting
the following objectives and milestones for the remainder of 2016 and beyond:
The shareholder letter can
be accessed via the investor relations section of Actinium's website http://ir.actiniumpharma.com/shareholder-letters.
Sandesh Seth, Actinium's
Executive Chairman stated, "Actinium set out to make 2016 a transformational year for the Company following the clearance
of our IND for Iomab-B at the end of 2015 and I think it is safe to say that we were successful. Reflecting on the first half of
2016, I could not be more pleased with all that we have accomplished, particularly the initiation of the pivotal Phase 3 clinical
trial for Iomab-B and the many opportunities that lie ahead for Actinium such as the Actimab-A Phase 2 clinical trial. The remainder
of 2016 will be focused on advancing our clinical programs, leveraging our technology platform and driving shareholder value through
continued and consistent execution of milestones."
Iomab-B is a radioimmunotherapy
consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by the Fred Hutchinson
Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially
useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications,
including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic
leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes,
BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most
healthy tissues. Iomab-B is being studied in the pivotal Phase 3 SIERRA trial and is designed to be used, upon approval, in preparing
relapsed or refractory AML patients over the age of 55 patients for hematopoietic stem cell transplant, commonly referred to as
bone marrow transplant.
About the SIERRA trial
SIERRA (Study of Iomab-B in Elderly Relapsed or Refractory AML) trial is a multi-center,
randomized, controlled pivotal Phase 3 study of Iomab-B in patients with relapsed or refractory Acute Myeloid Leukemia (AML) who
are over the age of 55. The Company established an agreement with the FDA that the path to a Biologics License Application (BLA)
submission could include the SIERRA trial, if it is successful. The primary endpoint in the pivotal Phase 3 trial is durable complete
remission, defined as a complete remission lasting at least 6 months and the secondary endpoint will be overall survival at one
year. There are currently no effective treatments approved by the FDA for AML in this patient population and there is no defined
standard of care. Iomab-B has completed several physician sponsored clinical trials examining its potential as a conditioning regimen
prior to HSCT in various blood cancers, including the Phase 1/2 study in relapsed and/or refractory AML patients. The results of
these studies in almost 300 patients have demonstrated the potential of Iomab-B to create a new treatment paradigm for bone marrow
transplants by: expanding the pool to ineligible patients who do not have any viable treatment options currently; enabling a shorter
and safer preparatory interval for HSCT; reducing post-transplant complications; and showing a clear survival benefit including
Actimab-A, Actinium's most
advanced alpha particle immunotherapy (APIT) program, is currently in a single arm, multicenter trial Phase 1/2 trial for patients
newly diagnosed with AML over the age of 60. Actimab-A is being developed as a first-line therapy and it has attracted support
from some of the leading experts at the most prestigious cancer treatment hospitals due to the potential of its safety and efficacy
profile. Actimab-A consists of the monoclonal antibody, HuM195, and the radioisotope, actinium-225. Actinium-225 decays by giving
off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of
which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. HuM195 is the humanized
version of M195 and is a monoclonal antibody that targets CD33, which is abundantly found on myeloid leukemia cells. Both the alpha
particle technology and HuM195 were initially developed at Memorial Sloan Kettering Cancer Center. Actimab-A is a second-generation
therapy from the Company's HuM195-Alpha program, which has now been studied in over 85 patients in four clinical trials.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc.
(www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics
for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on its proprietary delivery platform
for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in
conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used,
upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The
Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or relapsed AML patients over
the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing
its clinical development in a Phase 1/2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter
Forward-Looking Statements
for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking
statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's
current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth
in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial
performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium
Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information,
future events, or otherwise.
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.